Regulatory pre-requisites for CIS countries (Russia, Kazakhstan, Ukraine) MCQs With Answer

Introduction

Regulatory pre-requisites for CIS countries (Russia, Kazakhstan, Ukraine) MCQs With Answer

This quiz collection is designed for M.Pharm students preparing for advanced regulatory coursework and exams. It covers practical pre-requisites and country-specific requirements for drug registration, dossier format, language and labeling, GMP evidence, local representation, testing and stability, pharmacovigilance obligations, and import controls relevant to Russia, Kazakhstan and Ukraine. Questions emphasize differences between national and EAEU pathways, documentation expectations (GMP, CPP, CoA), and procedural steps such as local batch testing and language needs. Use these MCQs to strengthen understanding of regulatory strategy when planning registration and market entry into CIS markets.

Q1. Which regulatory body is primarily responsible for marketing authorization (registration) of medicines in the Russian Federation?

• The Federal Service for Surveillance in Healthcare (Roszdravnadzor)
• The Eurasian Economic Commission
• The State Expert Centre of the Ministry of Health of Ukraine
• The Ministry of Health of Kazakhstan

Correct Answer: The Federal Service for Surveillance in Healthcare (Roszdravnadzor)

Q2. When seeking simultaneous registration for Russia and Kazakhstan, which regulatory pathway is commonly used to harmonize dossiers?

• Unified Eurasian Economic Union (EAEU) registration pathway
• European Medicines Agency centralized procedure
• Separate independent national filings only
• WHO Prequalification submission

Correct Answer: Unified Eurasian Economic Union (EAEU) registration pathway

Q3. What is the principal language required for submission of the registration dossier and product labelling in Russia?

• Russian
• English
• Kazakh
• Ukrainian

Correct Answer: Russian

Q4. Is a local authorised representative or local marketing authorisation holder generally required for foreign companies registering medicines in Russia, Kazakhstan and Ukraine?

• Yes — a local authorised representative or local MAH is generally required
• No — the foreign manufacturer can act as MAH without local presence
• Only for biological products
• Only for controlled substances

Correct Answer: Yes — a local authorised representative or local MAH is generally required

Q5. Which document is the standard evidence that a manufacturing site complies with Good Manufacturing Practice (GMP) for regulatory submissions?

• A GMP certificate issued by a competent national regulatory authority
• A company brochure describing manufacturing
• A batch packing list
• A supplier invoice

Correct Answer: A GMP certificate issued by a competent national regulatory authority

Q6. Which dossier format is broadly accepted and expected by regulators in Russia, Kazakhstan and Ukraine for drug registration submissions?

• The ICH Common Technical Document (CTD) format
• The US New Drug Application (NDA) only
• National free-form dossier without structure
• Only eCTD XML submissions are accepted

Correct Answer: The ICH Common Technical Document (CTD) format

Q7. For generic oral solid dosage forms, what critical study is typically required by regulators in these CIS countries to demonstrate therapeutic equivalence?

• Bioequivalence study versus a reference product
• Only in vitro dissolution without in vivo studies
• Animal pharmacology studies only
• No comparative data — waiver for all generics

Correct Answer: Bioequivalence study versus a reference product

Q8. Which of the following may be specifically requested by Russian authorities prior to granting registration for an imported medicinal product?

• Analysis of a registration batch in a locally accredited laboratory
• Only a copy of the foreign marketing authorisation with no local testing
• Approval from EMA as the single requirement
• Manufacturing in Russia only

Correct Answer: Analysis of a registration batch in a locally accredited laboratory

Q9. What is the typical initial validity period for a marketing authorization (registration certificate) issued in Russia and Kazakhstan?

• Five years
• One year
• Ten years
• Permanent with no renewal required

Correct Answer: Five years

Q10. For complex biologic products, which regulatory step is commonly mandatory before approval in these countries?

• On-site GMP inspection of the manufacturing facility
• Only paperwork review without inspections
• No additional steps beyond small molecule drugs
• Local manufacturing in each country

Correct Answer: On-site GMP inspection of the manufacturing facility

Q11. What language(s) are required on primary labeling and package leaflets in Kazakhstan?

• Kazakh and Russian
• English only
• Russian only
• Ukrainian and Russian

Correct Answer: Kazakh and Russian

Q12. Which document demonstrates the quality attributes of incoming excipients or chemical substances and is often requested as part of the quality section of a dossier?

• Certificate of Analysis (CoA)
• Marketing plan
• Sales forecast
• Patient information leaflet

Correct Answer: Certificate of Analysis (CoA)

Q13. What pharmacovigilance capacity is expected from the marketing authorisation holder when registering drugs in these markets?

• Establish a local pharmacovigilance contact and system for adverse event reporting
• No pharmacovigilance obligations are required
• Only collect adverse events if requested by patients
• Pharmacovigilance must be managed exclusively by local wholesalers

Correct Answer: Establish a local pharmacovigilance contact and system for adverse event reporting

Q14. Before the first import of a registered medicinal product into Russia or Kazakhstan, which administrative document is commonly required?

• An import permit or customs clearance specific to pharmaceuticals
• A domestic sales contract only
• No documentation — only registration is sufficient
• A retail distribution licence for each pharmacy

Correct Answer: An import permit or customs clearance specific to pharmaceuticals

Q15. When submitting foreign-issued Certificates of Pharmaceutical Product (CPP) or GMP certificates, what is commonly required to validate those documents for Russian and some CIS submissions?

• Legalisation or apostille and certified Russian translation
• Only an e-mail copy is sufficient
• No validation required for foreign documents
• Translation into English only

Correct Answer: Legalisation or apostille and certified Russian translation

Q16. How many production batches are typically requested as part of the quality dossier to demonstrate reproducible manufacturing for registration?

• Three consecutive production batches
• One pilot batch only
• Ten batches minimum
• No batches; only process description

Correct Answer: Three consecutive production batches

Q17. Which organization in Ukraine is historically responsible for evaluation of dossiers and expert review before registration?

• The State Expert Centre (SEC) of the Ministry of Health of Ukraine
• The Eurasian Economic Commission
• Roszdravnadzor
• The Ministry of Health of Kazakhstan

Correct Answer: The State Expert Centre (SEC) of the Ministry of Health of Ukraine

Q18. The EAEU unified registration, once granted, allows marketing in which group of countries?

• Russia, Kazakhstan, Belarus, Armenia and Kyrgyzstan
• Russia, Ukraine and Moldova only
• Kazakhstan and Ukraine only
• All CIS countries without exception

Correct Answer: Russia, Kazakhstan, Belarus, Armenia and Kyrgyzstan

Q19. Which type of stability data set is commonly expected by these regulators to support a full registration?

• Long-term and accelerated stability data, typically across three batches
• Only accelerated stability studies are acceptable
• Stability data are not required at submission
• In-use stability only

Correct Answer: Long-term and accelerated stability data, typically across three batches

Q20. Compared to Russia and Kazakhstan, which statement correctly characterises Ukraine’s regulatory pathway?

• Ukraine operates a distinct national registration system and generally requires Ukrainian-language documentation
• Ukraine is fully covered by EAEU unified registration
• Ukraine accepts registration from Russia without additional review
• Ukraine requires no local authorised representative for foreign MAHs

Correct Answer: Ukraine operates a distinct national registration system and generally requires Ukrainian-language documentation

Download